Biomedical Research

Journal Banner

Efficacy and safety of metoprolol plus trimetazidine in treating coronary heart failure

The aim of this study was to observe the efficacy and safety of Metoprolol (Met) plus Trimetazidine (Tri) in the treatment of Coronary Heart Failure (CHF). From January 2012 to January, 200 patients with coronary heart disease and heart failure who were treated at our hospital were selected as research subjects and randomly divided into a Control group (group C) and an Observation group (group O), with 100 patients in each group. The total efficacy rate in group O was 91.0%, higher than the 74.0% in group C and the difference was statistically significant (P<0.05). The post-treatment 6-Minute Walk Test (6-MWT) distance in group O (302.6 ± 26.7 m) was significantly increased from that before treatment (144.5 ± 11.2 m; t=39.752, P<0.01). The 6-MWT distance in group C was significantly decreased from before (268.5 ± 22.6 m) to after treatment (140.6 ± 10.8 m; t=37.173, P<0.01). However, the 6MWT distance in group O was statistically significantly longer than that in group C (P<0.01). After treatment, the Left Ventricular Ejection fraction (LVEF) in group O was significantly higher than that in group C, with t=5.7012 by the intergroup t test (P<0.01). The Left Ventricular End-Systolic Dimension (LVESD) and Left Ventricular End-Diastolic Dimension (LVEDD) in group O were statistically significantly lower than those in group C (t=2.8405 and 3.1128, respectively; P<0.01). The Met+Tri combination as treatment for CHF can significantly improve patients’ cardiac functions, improve clinical efficacy, and prolong patient survival. Thus, it is worthy of clinical promotion owing to its safety and effectiveness.

Author(s): Yueqin Zhang